PHASE-II TRIAL OF MITOMYCIN-C IN SQUAMOUS-CELL CARCINOMA OF THE UTERINE CERVIX - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY

Fifty-six patients with advanced, persistent, or recurrent squamous ce ll carcinoma of the cenix not previously exposed to cytotoxic drugs, o ther than as radiosensitizers, were entered into a study of single-age nt 20 mg/m(2) mitomycin-C every 6 weeks, The overall response rate amo ng the 52 patients evaluable for response was 12% (three complete and three partial responses). Median response duration was 7.3 months, For the entire population, median progression-free interval was 3.0 month s, and median survival was 4.9 months, Among 27 patients with pelvic d isease only in previously radiated fields, two responses were observed (7%), whereas four responses were observed among 25 patients with ext rapelvic disease in nonradiated fields (16%), The most frequent and se vere adverse effects were the result of myelosuppression, Based on the modest level of activity observed, no further study of mitomycin-C in squamous cell carcinoma of the cenix is planned. (C) 1995 Academic Pr ess, Inc.